Format

Send to

Choose Destination
Blood. 2017 May 25;129(21):2829-2835. doi: 10.1182/blood-2017-03-754119. Epub 2017 Apr 17.

Clinical updates in adult immune thrombocytopenia.

Author information

1
Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA; and.
2
Division of Hematology, University of Washington School of Medicine, Seattle, WA.

Abstract

Immune thrombocytopenia (ITP) occurs in 2 to 4/100‚ÄČ000 adults and results in variable bleeding symptoms and thrombocytopenia. In the last decade, changes in our understanding of the pathophysiology of the disorder have led to the publication of new guidelines for the diagnosis and management of ITP and standards for terminology. Current evidence supports alternatives to splenectomy for second-line management of patients with persistently low platelet counts and bleeding. Long-term follow-up data suggest both efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of late remissions. Follow-up of patients who have undergone splenectomy for ITP reveals significant potential risks that should be discussed with patients and may influence clinician and patient choice of second-line therapy. Novel therapeutics are in development to address ongoing treatment gaps.

PMID:
28416506
PMCID:
PMC5813736
DOI:
10.1182/blood-2017-03-754119
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center